|
Call Replay | The Path To A COVID-19 Vaccine: An Interview With Dr. Kari Nadeau Healthcare & Health Policy Subscribers: CLICK HERE for event details (includes audio, video replays, and associated materials). |
To help our team navigate this intricate landscape over the past few months, we have held ongoing conversations with leading vaccine experts and academic epidemiologists. Yesterday, subscribers were given the opportunity to be a part of that conversation. If you didn't have a chance to join, please enjoy the replay of our fireside chat with Dr. Kari Nadeau that focused on her outlook for a COVID-19 vaccine including the timeline, challenges, promising candidates and platforms, and the outlook for success in the near- term. Key topics from the discussion include:
- Positive outlook for MRNA vaccine, some caveats on how much protection and how durable the response, though
- Handicapping all vaccines, a multi-target vaccine strategy much better than spike-protein-only strategies as COVID can enter cell through multiple docking sites
- Seasonal uptick in cases likely as weather cools, similar to flu
- Children are infected by COVID cousins, seems to offer protection
- COVID19 vaccine likely to be similar to flu in terms of effectiveness
SPEAKER PROFILE
Dr. Kari Nadeau is the Naddisy Foundation Endowed Professor of Medicine and Pediatrics and, Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. She is Section Chief in Asthma and Allergy in the Pulmonary, Allergy and Critical Care Division at Stanford. She is now the Sr. Director of Clinical Research for the Division of Hospital Medicine. Dr. Nadeau leads a team of specialists spanning allergy, asthma, and immunology across Stanford University. She has been a pioneer in the field of Translational Allergy and Immunology, both defining the mechanism of new therapies and then translating them clinically to make transformative changes in patients. She has led research in oncology, transplant and autoimmune trials and is a member of the National Steering Committee for the intramural clinical research programs at the NIH. She has also started 4 biotech companies in the Bay Area under Stanford patents and has worked in industry to shepherd two drugs through the FDA to approval.
Thomas Tobin
Managing Director
Twitter
LinkedIn
